Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation
April 11 2018 - 9:11AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
kidney disease, today announced that the company has received the
2018 Corporate Innovator Award from the National Kidney Foundation.
The award will be presented to Keryx today at the NKF Spring
Clinical Meetings in Austin, Texas.
“The Corporate Innovator Award was established
to recognize industry partners that advance the field of nephrology
by addressing an unmet medical need, or improving upon an existing
practice, therapeutic or technology,” said Kevin Longino, CEO,
National Kidney Foundation and a kidney transplant patient. “This
year, we are recognizing Keryx Biopharmaceuticals for their work in
developing innovative medicines for patients living with chronic
kidney disease.”
“Keryx is a team of approximately 200 committed
people working with passion to advance the care of people living
with kidney disease,” said John Neylan, M.D., chief medical officer
of Keryx Biopharmaceuticals. “We are honored to be recognized by
the National Kidney Foundation with this award.”
About Keryx Biopharmaceuticals,
Inc.Keryx Biopharmaceuticals, Inc., headquartered in
Boston, Massachusetts, is focused on the development and
commercialization of innovative medicines that provide unique and
meaningful advantages to people with kidney disease. The Keryx team
consists of approximately 200 committed people working with passion
to advance the care of people with this complex disease. This
dedication has resulted in two FDA-approved indications for Keryx’s
first medicine, Auryxia® (ferric citrate) tablets. For more
information about Keryx, please visit www.keryx.com.
Forward-looking Statements Some
of the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Among the factors that
could cause our actual results to differ materially are the
following: our ability to successfully market Auryxia; whether we
can maintain our operating expenses to projected levels while
continuing our current clinical, regulatory and commercial
activities; our ability to continue to supply Auryxia to the
market; the risk that increased utilization by Medicare Part D
subscribers will increase our gross-to-net adjustment greater than
we anticipate; and other risk factors identified from time to time
in our reports filed with the Securities and Exchange Commission.
Any forward-looking statements set forth in this press release
speak only as of the date of this press release. We do not
undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available at
http://www.keryx.com. The information found on our website is not
incorporated by reference into this press release and is included
for reference purposes only.
KERYX BIOPHARMACEUTICALS CONTACTAmy Sullivan,
SVP, Corporate AffairsT: 617.466.3519amy.sullivan@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024